Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell-based therapy applications

被引:527
作者
Doucet, C
Ernou, I
Zhang, YZ
Llense, JR
Begot, L
Holy, X
Lataillade, JJ
机构
[1] Ctr Transfus Sanguine Armees Jean Julliard, Dept Rech, F-92141 Clamart, France
[2] Univ Paris 06, Hematol Lab, Paris 12, France
[3] Aerospatiale, Dept Physiol, Inst Med, Serv Sante Armees, Bretigny Sur Orge, France
关键词
D O I
10.1002/jcp.20391
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Mesenchymal stem cells (MSCs) are considered as emergent "universal" cells and various tissue repair programs using MSCs are in development. In vitro expansion of MSCs is conventionally achieved in medium containing fetal calf serum (FCS) and is increased by addition of growth factors. However, for widespread clinical applications, contact of MSCs with FCS must be minimized since it is a putative source of prion or virus transmission. Therefore, because platelets are a natural source of growth factors, we sought to investigate in vitro MSC expansion in response to platelet lysates (PL) obtained from platelet-rich plasma. Human MSCs were expanded in FCS (+/- bFGF)- or PL-supplemented medium through a process of subculture. We demonstrated that PL-containing medium is enriched by growth factors (platelet-derived growth factors (PDGFs), basic fibroblast growth factor (bFGF), transforming growth factor TGF-beta), insulin-like growth factor-1 (IGF-1)...) and showed that PL is able to promote MSC expansion, to decrease the time required to reach confluence, and to increase CFU-F size, as compared to the FCS medium. Furthermore, we demonstrated that MSCs cultured in the presence of PL maintain their osteogenic, chondrogenic, and adipogenic differentiation properties and retain their immunosuppressive activity. Therefore, we propose that PL may be a powerful and safe substitute for FCS in development of tissue- and cellular-engineered products in clinical settings using MSCs.
引用
收藏
页码:228 / 236
页数:9
相关论文
共 34 条
[31]   Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF [J].
Tsutsumi, S ;
Shimazu, A ;
Miyazaki, K ;
Pan, H ;
Koike, C ;
Yoshida, E ;
Takagishi, K ;
Kato, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 288 (02) :413-419
[32]   IGF-I does not affect the proliferation or early osteogenic differentiation of human marrow stromal cells [J].
Walsh, S ;
Jefferiss, CM ;
Stewart, K ;
Beresford, JN .
BONE, 2003, 33 (01) :80-89
[33]   Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count [J].
Weibrich, G ;
Kleis, WKG ;
Hafner, G ;
Hitzler, WE .
JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2002, 30 (02) :97-102
[34]   Basic studies on the clinical applications of platelet-rich plasma [J].
Yazawa, M ;
Ogata, H ;
Nakajima, T ;
Mori, T ;
Watanabe, N ;
Handa, M .
CELL TRANSPLANTATION, 2003, 12 (05) :509-518